Trending Now
  • Independence Day Op-Ed Frames Consumer Legal Funding as the Freedom to Pursue Justice

Key Takeaways from LFJ’s  Virtual Town Hall: PACCAR Revisited

By John Freund |

Key Takeaways from LFJ’s  Virtual Town Hall: PACCAR Revisited

On Thursday August 15th, LFJ hosted a Virtual Town Hall titled ‘PACCAR Revisited.’ The live event revisited the PACCAR decision one year later and explored what the future holds for legal funding in the UK and beyond.

Panelists included Ben Knowles (BK), Chair International Arbitration at Clyde & Co LLP, Robert Marven (RM), Barrister at 4 New Square, Nicholas Marler (NM), Head of Technical Underwriting at Litica Ltd, and Neil Purslow (NP), Founder and Chief Investment Officer, Therium Capital Management Limited. The panel discussion was moderated by Tets Ishikawa, Managing Director of LionFish Litigation Finance Limited.

Below are some key takeaways from the event:

We don’t hear much from insurers in regard to the PACCAR issue. Nicholas, from an insurer’s perspective, what are your thoughts?

NM: The ATE insurers’ odyssey through the world of PACCAR is in some ways quite different from that of a litigation funder. At first bluff, you might think that PACCAR doesn’t have anything to do with insurers because it has to do with litigation funding agreements, and you’d never catch an insurer signing an LFA, so what’s the problem?

If you scratch a little deeper though, the reality is quite different. If you as an insurer, insure a funder, and the funder gives an adverse costs indemnity to the claimant, then all of a sudden, the insurer’s contractual fortunes are tied to the funders. If the LFA is unenforceable, then not only can the insurer not collect its contingent premium if there’s a success, but the coverage provided to the funder has vanished–this is because the LFA is unenforceable.

We actually had this exact experience play out. An opportunistic claimant sought to cut the funder out, because it felt emboldened to do so as a result of the PACCAR decision. When they were informed that doing so would void their insurance, which was to their benefit, they magically found the goodwill necessary to resolve things with their funder and an amicable solution was quickly found.

You’ve touched on enforceability. Given how central that is to the heart of the PACCAR issue, Robert, can you share some insights and perspectives on this corse issue?

RM: There are essentially two views on the concept of enforceability. One is that it essentially says there isn’t anything wrong with the contract, just that it can’t be enforced. There is another view which says that the contract is unenforceable, that it is an illegal contract. I don’t agree with that. It seems this is one of the paradoxes of PACCAR, it seems to have rendered unenforceable funding agreements that were perfectly legal under common law.

A lack of enforceability is important to understand as a two-way street. It means the funder cannot enforce, and it also means the claimant cannot enforce. And this is the key to understanding why things have been put right in cases that are still ongoing. A claimant who says to a funder ‘I don’t have to pay you anymore,’ well, a funder could say to the same token, ‘I don’t have to fund your case anymore.’ And we have seen cases that have been over or very nearly over, where the claimants think they don’t need the funder anymore and saying ‘thank you very much, I needed the funding but I don’t have to pay you.’ Or ‘I did pay you, but I want the money back.’

This is where it’s important to remember that enforceability is a two-way street. If all sides want to continue to carry on, then everyone has an incentive in fixing the problem. It’s only where those interests converge that seem to have led to a significant litigation dispute.

Ben, from your perspective, how do you think this affects the UKs standing as a legal jurisdiction?

BK: PACCAR created a mess, and it was an expensive mess, irrespective of where we’re going to end up. There’s been a lot of lawyer’s time figuring out what PACCAR means and where we’re going to go. The PACCAR fix, as I call it, would have cleared things up to some extend. But the absence of that means some of this uncertainty will continue. And uncertainty means additional costs.

We have these various appeals on the funding agreements out there at the moment. I would expect that in some of these cases, there will be appeals that go to the Court of Appeals, and potentially, all the way up to the Supreme Court. My feeling is, when there’s a case to be funded, lawyers will find a way to get that case funded. Although I’d imagine there will be a risk premium attached to that funding, not least because everybody will be getting their funding agreements checked, double-checked and triple-checked. And you may have lawyers who disagree on what’s permissible, and that leads to additional costs at the start of the case.

This session is about PACCAR, but we’d be remiss not to talk about the CJC, given how the two issues merge. Neil, you’re on the consultation group for the CJC review. Are there any insights you’re able to share?

NP: There’s now a working party reporting up to the CJC. We’re expecting an interim report from that working party to come out in late summer or early autumn, and there will be a consultation, and then the final report in the middle of next year. So we’ve put on quite a tight timeline.

From an industry perspective, this review is welcome, unless you’re opposed to the idea of talking about regulation, which I don’t think the industry is. This is a sensible organizational group that is considering these points in a proper and thoughtful way. I would encourage people to get behind the work that ILFA and ALFA are doing here, and I’d also encourage funders to get involved in the consultation phase as well. It’s very important that the CJC are thinking about these points with a full and proper understanding of how funding actually works, so they can understand the impact.

I think it’s also important that the industry makes sure that the review takes place in a proper context, and by ‘proper context’ I mean that there is an understanding that funding does have benefits. So the review should look at how good responsible funding can be encouraged and those benefits can be maximized, rather than looking at funding as a suspicious thing that needs to be controlled and is just a risk. I think there is a very positive message for funding that needs to be emphasized, and I think the CJC needs to look at it through this positive lens, and I’m confident that they will.

To view the entire digital event, click here.

About the author

John Freund

John Freund

Commercial

View All

Omni Bridgeway Marks 40th Anniversary With Band 1 Chambers 2026 Rankings

Omni Bridgeway has secured top-tier recognition in the Chambers and Partners Litigation Support Guide 2026, earning Band 1 rankings in both Litigation Funding and Global Asset Tracing and Recovery. The recognition arrives as the ASX-listed funder marks its 40th anniversary, underscoring its standing as one of the largest and longest-established players in global legal finance.

According to Omni Bridgeway, the firm was ranked Band 1 across International Arbitration, US Intellectual Property, Europe, Singapore, the Middle East, and Canada, and Band 2 in the United Kingdom, United States, and Latin America. With operations spanning 24 international locations, the funder positions itself as a global leader in legal finance and risk management.

Central to Omni Bridgeway's pitch is an end-to-end capability that runs from case inception through post-judgment enforcement and recovery — a breadth reflected in its separate Band 1 ranking for global asset tracing and recovery, an area demanding cross-border coordination and strategic execution. The firm emphasizes disciplined capital deployment and a focus on realized outcomes across jurisdictions.

The Chambers rankings, based on months of independent research and confidential client interviews, are among the legal industry's most closely watched benchmarks. One client, quoted in connection with the recognition, likened litigation funding to investing: "sometimes money is just money, but other times, you have a partner that cares about their investment and wants it to grow." For Omni Bridgeway, four decades in, the results reaffirm a market-leading position as the funding sector continues to professionalize and expand.

UK’s FCA Motor Finance Redress Scheme Partly Suspended Amid Legal Challenges

The UK Financial Conduct Authority's roughly £9.1 billion motor finance redress scheme has been partly suspended after the Upper Tribunal agreed to pause key elements pending the outcome of four legal challenges. Under the suspension, lenders are no longer required to calculate compensation, make payments, or contact eligible consumers, though they must continue to comply with the rules that remain in force.

As reported by Reuters, the challenges come from three car finance lenders — CA Auto Finance, Mercedes-Benz Financial Services, and Volkswagen Financial Services — alongside the consumer group Consumer Voice, which is pressing for larger payouts. All four argue that the rules underpinning the mass redress scheme are unlawful in whole or in part and are asking the court to quash or invalidate them.

The scheme is intended to compensate motor finance customers treated unfairly between 2007 and 2024, a period in which the FCA says undisclosed commission arrangements between lenders and dealers incentivized brokers to inflate interest rates. Hearings before the Upper Tribunal are expected around mid-November 2026 and could extend into 2027, with actual redress potentially delayed to 2027 or beyond.

The suspension adds fresh uncertainty to a landscape in which funded commission litigation is already advancing through the courts — including the recent Court of Appeal ruling permitting omnibus claim forms — and sharpens the question of whether affected consumers will ultimately recover through the regulator's scheme or through the courts.

AdvoCap Launches Nationwide Case Expense Insurance for Contingent-Fee Firms

AdvoCap Insurance Agency, a subsidiary of case-cost financier Advocate Capital, has launched a Case Expense Insurance Program aimed at plaintiff and contingent-fee law firms across the United States. The product is designed to protect the substantial sums firms advance to move litigation forward, adding a risk-management layer to a corner of the market where firms have traditionally shouldered those costs alone.

According to PR Newswire, the program covers eligible case expenses in qualifying matters, including expert witness fees, medical record retrieval, deposition costs, and accident reconstruction. By insuring against unrecovered litigation expenses, the offering aims to strengthen firm balance sheets, improve cash-flow predictability, and give attorneys greater confidence to invest in meritorious cases.

"Plaintiff firms routinely make significant financial commitments before seeing any return," said Donna Jones, President of Advocate Capital and AdvoCap Insurance. "This program provides an additional layer of protection that can help firms grow strategically, manage uncertainty, and continue investing in the cases that matter most to their clients."

The launch reflects the continued convergence of litigation finance and insurance, as providers build products around the capital that contingent-fee practices tie up in active cases. For firms weighing how aggressively to fund their dockets, tools that de-risk advanced case costs increasingly sit alongside traditional case-expense financing as part of the plaintiff bar's capital toolkit.